Search
Acipimox
go.drugbank.com/drugs/DB09055ApprovedInvestigationalAdverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. … Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL.
Influenza B virus B/Phuket/3073/2013 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10779ApprovedInvestigationalInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Fluarix Tetra Injektionssuspension in einer FertigspritzePrezatide copper
go.drugbank.com/drugs/DB14683InvestigationalPrezatide is used in cosmetic products for the skin and hair. … It is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer are currently being investigated.
Enzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular … [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022.
Repotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigationalRepotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the … This approval is based on favorable results from the TRIDENT-1 study, where the objective response rate was 79% in TKI-naive patients and 38% in TKI-pretreated patients respectively.[L48741]
Calcium polycarbophil
go.drugbank.com/drugs/DB14684ApprovedIt is insoluble in water, dilute acids, and dilute alkali. … Based on its chemical structure, it is a synthetic polymer of polyacrylic acid cross-linked with divinyl glycol presenting a calcium atom as a counter-ion.
Categories: Compounds used in a research, industrial, or household settingProducts: Fiber-ON-tabletDronabinol
go.drugbank.com/drugs/DB00470ApprovedIllicitInvestigationalDue to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting … Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction
Synonyms: 3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-olTemoporfin
go.drugbank.com/drugs/DB11630ApprovedTemoporfin is a photosensitizing agent used in the treatment of squamous cell carcinoma of the head and neck [FDA Label]. … It was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan.
Categories: Sensitizers Used in Photodynamic/radiation TherapyForeskin fibroblast (neonatal)
go.drugbank.com/drugs/DB10770ApprovedThe impact of diabetic foot ulcers (DFU) on individuals and society is devastating. Failure to observe proper wound care in this condition often results in amputation. … Dermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997.